Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalpiciclib - Jiangsu Hengrui Medicine Co

Next Previous
Drug Profile

Dalpiciclib - Jiangsu Hengrui Medicine Co

Alternative Names: AiRuiKang; Dalpiciclib Isethionate - Jiangsu Hengrui Medicine Co; SHR-6390

Latest Information Update: 16 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Atridia; Jiangsu Hengrui Medicine Co.; Peking University; Shanghai Jiaotong University School of Medicine; Sheng Jing Hospital; Tianjin University
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Ketones; Piperidines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 negative breast cancer
  • Phase II Breast cancer; HER2 positive breast cancer
  • Phase I/II Malignant melanoma
  • No development reported Gastric cancer; Head and neck cancer; Solid tumours

Most Recent Events

  • 09 Dec 2025 Updated efficacy and adverse events data from the phase III trial in Her2 negative Breast cancer presented at the 48th Annual San Antonio Breast Cancer Symposium (SABCS-2025)
  • 30 May 2025 Efficacy and adverse events from phase-III DAWNA-A trial in Her2 negative Breast cancer presented at 61st Annual Meeting of the American Society of Clinical Oncology(ASCO-2025)
  • 28 Dec 2024 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Combination therapy, Neoadjuvant therapy) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top